The authorized generic version of Covis Pharma’s Rilutek is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy.
Riluzole has become the ninth generic product launched by Rising Pharmaceuticals in 2013.
The market sales for Riluzole in the US were around $64m for the twelve months ended on 31 December 2012, as per IMS Health data.
ACETO markets, sells and distributes products for human health (finished dosage form generics and nutraceutical products), pharmaceutical ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and performance chemicals (specialty chemicals and agricultural protection products).